Summary
Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016’, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects
- The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ironwood Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
Theravance Biopharma, Inc.
Valeant Pharmaceuticals International, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Opioid-Induced Constipation (OIC) Overview 6
Therapeutics Development 7
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 7
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 8
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Opioid-Induced Constipation (OIC) - Products under Development by Companies 11
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 12
Ironwood Pharmaceuticals, Inc. 12
Shionogi & Co., Ltd. 13
Sucampo Pharmaceuticals, Inc. 14
Synergy Pharmaceuticals, Inc. 15
Theravance Biopharma, Inc. 16
Valeant Pharmaceuticals International, Inc. 17
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(axelopran sulfate + oxycodone hydrochloride) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
axelopran sulfate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dolcanatide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
linaclotide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
lubiprostone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
methylnaltrexone bromide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
methylnaltrexone bromide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
naldemedine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 43
Opioid-Induced Constipation (OIC) - Dormant Projects 61
Opioid-Induced Constipation (OIC) - Discontinued Products 62
Opioid-Induced Constipation (OIC) - Product Development Milestones 63
Featured News & Press Releases 63
Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation 63
Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015 63
Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 65
Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 65
Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients 65
Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation 66
May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 66
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 67
Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 67
Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 12
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2016 13
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 14
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 15
Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma, Inc., H1 2016 16
Opioid-Induced Constipation (OIC) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Assessment by Combination Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2016 43
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2016 61
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26
